NCT01929720

Brief Summary

This randomized clinical trial studies a cognitive-behavioral intervention to treat worry, uncertainty, and insomnia in cancer survivors. Counseling may reduce anxiety and insomnia as well as improve the well-being and quality of life of cancer survivors. This study also explores the neuro-immunologic correlates of anxiety and insomnia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2011

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2011

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

March 13, 2013

Completed
6 months until next milestone

First Posted

Study publicly available on registry

August 28, 2013

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2014

Completed
Last Updated

April 5, 2017

Status Verified

April 1, 2017

Enrollment Period

3.1 years

First QC Date

March 13, 2013

Last Update Submit

April 4, 2017

Conditions

Keywords

cancercancer survivorsworryinsomniasymptomsfatiguedepressionanxiety

Outcome Measures

Primary Outcomes (3)

  • Changes in worry on the Penn State Worry Questionnaire

    A linear mixed model will be used to evaluate the change from pre to post on the Penn State Worry Questionnaire. The model will include group (treatment vs. control), time (pre vs. post), and group-time interaction effects. If the outcome measure is not normally distributed with equal variance across groups, then the outcomes will be log transformed in order to meet these assumptions for the mixed models.

    From baseline to 6 weeks

  • Changes in sleep efficiency on the Insomnia Severity Index

    A linear mixed model will be used to evaluate the change from pre to post on the Insomnia Severity Index. The model will include group (treatment vs. control), time (pre vs. post), and group-time interaction effects. If the outcome measure is not normally distributed with equal variance across groups, then this outcome will be log transformed in order to meet these assumptions for the mixed models.

    From baseline to 6 weeks

  • Changes in intolerance of uncertainty on the Intolerance of Uncertainty Scale

    A linear mixed model will be used to evaluate the change from pre to post on the Intolerance of Uncertainty Scale . The model will include group (treatment vs. control), time (pre vs. post), and group-time interaction effects. If the outcome measure is not normally distributed with equal variance across groups, then the outcome will be log transformed in order to meet these assumptions for the mixed models.

    From baseline to 6 weeks

Secondary Outcomes (3)

  • Levels of cortisol

    Baseline

  • Levels of pro and anti-inflammatory cytokines

    Baseline

  • Levels of myeloid-derived suppressor cells (MDSC)

    Baseline

Study Arms (2)

Arm I (CBT for worry, uncertainty & insomnia)

EXPERIMENTAL

Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. Patients participate in a Behavioral Intervention (cognitive-behavioral therapy) in which they receive education on the components of anxiety (physical cognitive, and behavioral) and practice relaxation techniques and behavioral sleep strategies in weeks 2-5.

Behavioral: Cognitive-behavioral therapy for worry, uncertainty & insomnia

Arm II (wait-list control)

ACTIVE COMPARATOR

Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. This is a wait-list comparison, so after six weeks, patients in the control group complete the behavioral (cognitive-behavioral therapy)intervention for worry, uncertainty, and insomnia.

Behavioral: Cognitive-behavioral therapy for worry, uncertainty & insomnia

Interventions

This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.

Also known as: Cognitive-behavioral Therapy, Acceptance and Commitment Therapy, Psychological Intervention, Behavior Therapy, Behavioral Modification, Behavioral Therapy, Behavioral Treatment
Arm I (CBT for worry, uncertainty & insomnia)Arm II (wait-list control)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • lung cancer
  • stage III or IV colorectal cancer
  • pancreatic cancer
  • esophageal cancer
  • multiple myeloma
  • leukemia
  • stage IIIC and IV melanoma
  • ovarian cancer
  • stage III \& IV cervical cancer
  • stage III \& IV uterine cancer
  • stage IIIB, IIIC, and IV breast cancer
  • glioblastoma multiforme
  • early relapse (\< 1 year) lymphoma

You may not qualify if:

  • co-morbid immunologic disease (i.e. rheumatoid arthritis, systemic lupus)
  • neurologic disease (i.e. multiple sclerosis, Parkinson's, Alzheimer's) that would affect neuro-immune assessment or completion of study questionnaires
  • mania (if patient has bipolar disorder)
  • active substance abuse disorders such as alcohol dependence and cocaine abuse will also be excluded

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wexner Medical Center at The Ohio State University Department of Psychiatry

Columbus, Ohio, 43210, United States

Location

Related Publications (2)

  • Cai Z, Tang Y, Liu C, Li H, Zhao G, Zhao Z, Zhang B. Cognitive behavioural therapy for insomnia in people with cancer. Cochrane Database Syst Rev. 2025 Oct 31;10(10):CD015176. doi: 10.1002/14651858.CD015176.pub2.

  • Wells-Di Gregorio S, Flowers S, Peng J, Marks DR, Probst D, Zaleta A, Benson D, Cohn DE, Lustberg M, Carson W, Magalang U, Baltimore S, Ancoli-Israel S. Combined Treatment With Cognitive Behavioral Therapy for Insomnia and Acceptance and Commitment Therapy Enhances Objective and Subjective Reports of Sleep in Patients With Advanced Cancer. Psychooncology. 2025 Apr;34(4):e70141. doi: 10.1002/pon.70141.

Related Links

MeSH Terms

Conditions

Anxiety DisordersSleep Wake DisordersSleep Initiation and Maintenance DisordersFatiguePainDepressionEsophageal NeoplasmsPancreatic NeoplasmsLeukemiaLung NeoplasmsMultiple MyelomaOvarian NeoplasmsUterine NeoplasmsGlioblastomaLymphomaNeoplasms

Interventions

Cognitive Behavioral TherapyUncertaintyAcceptance and Commitment TherapyPsychosocial InterventionBehavior Therapy

Condition Hierarchy (Ancestors)

Mental DisordersNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsSleep Disorders, IntrinsicDyssomniasBehavioral SymptomsBehaviorGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteHead and Neck NeoplasmsDigestive System DiseasesEsophageal DiseasesGastrointestinal DiseasesEndocrine Gland NeoplasmsPancreatic DiseasesEndocrine System DiseasesNeoplasms by Histologic TypeHematologic DiseasesHemic and Lymphatic DiseasesRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesNeoplasms, Plasma CellHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System DiseasesOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesGonadal DisordersUterine DiseasesAstrocytomaGliomaNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueLymphatic Diseases

Intervention Hierarchy (Ancestors)

PsychotherapyBehavioral Disciplines and ActivitiesProbabilityStatistics as TopicEpidemiologic MethodsInvestigative TechniquesMathematical ConceptsHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Sharla Wells-Di Gregorio, Ph.D.

    Ohio State University Comprehensive Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 13, 2013

First Posted

August 28, 2013

Study Start

August 1, 2011

Primary Completion

September 1, 2014

Study Completion

September 1, 2014

Last Updated

April 5, 2017

Record last verified: 2017-04

Locations